The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10439 malaria professionals are enjoying the free benefits of MalariaWorld today

cerebral malaria

NOT Open Access | Cerebral malaria in a man with Plasmodium vivax mono-infection: a case report

October 6, 2016 - 17:25 -- NOT Open Access
Author(s): 
Himanshu Gupta, Pushwinder Dhunputh, Ankita N Bhatt, Kapaettu Satyamoorthy, and Shashikiran Umakanth
Reference: 
Trop Doct October 2016 vol. 46 no. 4 241-245

Cerebral malaria (CM) is a diffuse encephalopathy associated with coma and seizures commonly caused by Plasmodium falciparum (P. falciparum) in children with severe malaria.

Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria

August 26, 2016 - 17:57 -- Open Access
Author(s): 
Brian DellaValle, Casper Hempel, Trine Staalsoe, Flemming Fryd Johansen and Jørgen Anders Lindholm Kurtzhals
Reference: 
Malaria Journal 2016 15:427, 24 August 2016

Despite the breadth of models where GLP-1 is neuroprotective, ECM was not affected by liraglutide providing important insight into the pathogenesis of ECM.

Plasma levels of eight different mediators and their potential as biomarkers of various clinical malaria conditions in African children

July 2, 2016 - 16:13 -- Open Access
Author(s): 
Rachida Tahar, Catarina Albergaria, Neil Zeghidour, Vincent Foumane Ngane, Leonardo K. Basco and Christian Roussilhon
Reference: 
Malaria Journal 2016 15:337, 29 June 2016

The results indicate that the simultaneous evaluation of these bioactive molecules as quantifiable blood parameters may be helpful to get a better insight into the clinical syndromes in children with malaria.

Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives

June 28, 2016 - 16:34 -- Open Access
Author(s): 
Remington L. Nevin and Ashley M. Croft
Reference: 
Malaria Journal 2016 15:332, 22 June 2016

The modern medical literature implicates malaria, and particularly the potentially fatal form of cerebral malaria, with a risk of neurocognitive impairment.

Medical Treatment: 

Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria

May 11, 2016 - 16:14 -- Open Access
Author(s): 
Neda Moradin, Sabrina Torre, Susan Gauthier, Mifong Tam, Jalal Hawari, Kirsten Vandercruyssen, Bart De Spiegeleer, Anny Fortin, Mary M. Stevenson and Philippe Gros
Reference: 
Malaria Journal 2016 15:260, 6 May 2016

These findings indicate that inclusion of Cys in current formulations of ACT, or its use as adjunct therapy could improve the anti-plasmodial activity of artemisinin, decrease mortality in cerebral malaria patients, and prevent or delay the development and spread of artemisinin resistance.

Medical Treatment: 

Early prediction of cerebral malaria by 1H NMR based metabolomics

April 12, 2016 - 16:56 -- Open Access
Author(s): 
Soumita Ghosh, Arjun Sengupta, Shobhona Sharma and Haripalsingh M. Sonawat
Reference: 
Malaria Journal 2016 15:198, 12 April 2016

This study clearly demonstrates the possibility of differentiating and identifying animals with CM at an early, pre-clinical stage.

Endothelin-1 Mediates Brain Microvascular Dysfunction Leading to Long-Term Cognitive Impairment in a Model of Experimental Cerebral Malaria

April 2, 2016 - 16:55 -- Open Access
Author(s): 
Brandi D. Freeman, Yuri C. Martins, Oscar B. Akide-Ndunge, Fernando P. Bruno, Hua Wang, Herbert B. Tanowitz, David C. Spray, Mahalia S. Desruisseaux
Reference: 
PLoS Pathog 12(3): e1005477

Plasmodium falciparum infection causes a wide spectrum of diseases, including cerebral malaria, a potentially life-threatening encephalopathy.

Cerebral malaria is associated with long-term mental health disorders: a cross sectional survey of a long-term cohort

April 2, 2016 - 16:19 -- Open Access
Author(s): 
Richard Idro, Angelina Kakooza-Mwesige, Joyce Nalugya, et al.
Reference: 
Malaria Journal 2016 15:184, 31 March 2016

Cerebral malaria may predispose children to mental health disorders, possibly as a consequence of ischaemic neural injury.

NOT Open Access | New pentasubstituted pyrrole hybrid atorvastatin–quinoline derivatives with antiplasmodial activity

March 29, 2016 - 17:53 -- NOT Open Access
Author(s): 
Rita C.C. Carvalho, Wagner A. Martins, Tayara P. Silva, Carlos R. Kaiser, Mônica M. Bastos, Luiz C.S. Pinheiro, Antoniana U. Krettli, Núbia Boechat
Reference: 
Bioorganic & Medicinal Chemistry Letters Volume 26, Issue 8, 15 April 2016, Pages 1881–1884

Cerebral malaria is caused by Plasmodium falciparum. Atorvastatin (AVA) is a pentasubstituted pyrrole, which has been tested as an adjuvant in the treatment of cerebral malaria.

NOT Open Access | Plasmodium vivax Malaria Presenting with Multifocal Hemorrhagic Brain Infarcts in a School-going Child

March 19, 2016 - 18:42 -- NOT Open Access
Author(s): 
Santosh Kumar Rathia, Jhuma Sankar, Devasenathipathy Kandasamy, and Rakesh Lodha
Reference: 
J Trop Pediatr March 10, 2016

Cerebral malaria is a well-known complication of Plasmodium falciparum malaria.

Pages

Subscribe to RSS - cerebral malaria